<DOC>
	<DOCNO>NCT02260375</DOCNO>
	<brief_summary>The general aim present study test cell therapy third-party allogeneic ex-vivo expand MSCs strategy induce tolerance liver transplant recipient . MSCs prepare accordingly establish protocol , start diagnostic sample bone marrow aspirate ( 2-5 mL ) use remnant bag filter end bone marrow infusion . From sample , MSCs expand GMP approve facility use present study patient undergo liver transplantation .</brief_summary>
	<brief_title>MSC Therapy Liver Transplantation</brief_title>
	<detailed_description />
	<criteria>For study , follow inclusion criterion fulfil start withdrawal drug 1 year posttransplant : First liver transplant Capable understand purpose risk study Written inform consent Specific contraindication MSC infusion Any clinical relevant condition might affect study participation and/or study result Pregnant woman nurse mother Unwillingness inability follow study protocol investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mesenchymal stromal cell ; liver transplantation ; tolerance .</keyword>
</DOC>